Cellosaurus cell line SNB-78 (CVCL_B321)

• Mutation; HGNC; 11998; TP53; Simple; p.Pro223Ala (c.667C>G); Zygosity=Unspecified (PubMed=15900046).
  

PubMed=3121170
Gross J.L., Behrens D.L., Mullins D.E., Kornblith P.L., Dexter D.L.
Plasminogen activator and inhibitor activity in human glioma cells and modulation by sodium butyrate.
Cancer Res. 48:291-296(1988)

PubMed=2041050; DOI=10.1093/jnci/83.11.757
Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D., Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
J. Natl. Cancer Inst. 83:757-766(1991)

DOI=10.1016/B978-0-12-333530-2.50005-8
Nister M., Westermark B.
Human glioma cell lines.
(In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.17-42; Academic Press; New York (1994)

PubMed=15900046; DOI=10.1093/jnci/dji133
Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y., Yamazaki K., Hamada J.-i., Tada M., Moriuchi T., Ishikawa Y., Kato Y., Tomoda H., Yamori T., Tsuruo T.
p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target.
J. Natl. Cancer Inst. 97:765-777(2005)

PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017
Kong D.-X., Yamori T.
JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.
Bioorg. Med. Chem. 20:1947-1951(2012)